- Investing.com
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Leadership Shift | Explore Fortrea's strategic pivot as new CEO Anshul Thakral takes the helm, promising fresh perspectives and potential operational enhancements |
Financial Resilience | Delve into Fortrea's mixed financial performance, featuring improved margins and a top-line beat, despite bookings challenges and industry headwinds |
Market Positioning | Learn how Fortrea, a mid-sized CRO with $2.69B annual revenue, navigates a competitive landscape dominated by larger players amid macroeconomic uncertainties |
Future Outlook | Analyst price targets range from $5 to $12, reflecting varied views on Fortrea's growth potential and ability to capitalize on margin improvement initiatives |
Metrics to compare | FTRE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFTREPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −2.2x | −0.5x | |
PEG Ratio | 0.00 | −0.17 | 0.00 | |
Price/Book | 1.2x | 1.2x | 2.6x | |
Price / LTM Sales | 0.3x | 1.9x | 3.3x | |
Upside (Analyst Target) | −11.4% | 30.4% | 40.6% | |
Fair Value Upside | Unlock | 23.3% | 5.3% | Unlock |